A61K 2039/57
Medicinal preparations containing antigens or antibodies: characterised by the type of response
Official title: {characterised by the type of response, e.g. Th1, Th2}
A61K2039/57 (Medicinal preparations containing antigens or antibodies: characterised by the type of response) appears on 4,098 US grants and 7,951 published applications in this corpus.
Search patents in A61K- Granted patents
- 4,098
- Published applications
- 7,951
- Assignees
- 2,557
- Inventors
- 12,503
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 2 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 2 | 0 |
| 1987 | 3 | 0 |
| 1988 | 2 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 2 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 2 | 0 |
| 1996 | 4 | 0 |
| 1997 | 9 | 0 |
| 1998 | 21 | 0 |
| 1999 | 19 | 0 |
| 2000 | 22 | 0 |
| 2001 | 28 | 19 |
| 2002 | 27 | 85 |
| 2003 | 34 | 136 |
| 2004 | 36 | 159 |
| 2005 | 47 | 134 |
| 2006 | 44 | 124 |
| 2007 | 48 | 108 |
| 2008 | 40 | 113 |
| 2009 | 71 | 157 |
| 2010 | 68 | 155 |
| 2011 | 65 | 189 |
| 2012 | 70 | 178 |
| 2013 | 85 | 185 |
| 2014 | 144 | 217 |
| 2015 | 147 | 288 |
| 2016 | 237 | 474 |
| 2017 | 223 | 542 |
| 2018 | 339 | 466 |
| 2019 | 358 | 450 |
| 2020 | 336 | 490 |
| 2021 | 346 | 494 |
| 2022 | 291 | 544 |
| 2023 | 228 | 618 |
| 2024 | 249 | 652 |
| 2025 | 283 | 591 |
| 2026 | 164 | 383 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Preventing and treating amyloid-beta deposition by stimulation of innate immunity6 Oct 2026US 12,751,964 B2New York University
- Lipid nanoparticles comprising sterols and mRNA6 Oct 2026US 12,751,999 B2eTheRNA Immunitherapies NV
- Mutant influenza B/Victoria lineage virus hemagglutinin proteins6 Oct 2026US 12,752,001 B2ModernaTX, Inc.
- Polypeptides, compositions, and their use to treat or limit development of an infection6 Oct 2026US 12,752,002 B2University of Washington
- Lipidated FLIPr and uses thereof in vaccine6 Oct 2026US 12,752,003 B2National Health Research Institutes
- Preparation of tolerizing nanoparticles for the treatment of primary biliary cholangitis8 Oct 2026US 2026/0306598 A1Cour Pharmaceuticals Development Company, Inc.
- Compositions and methods for generating immunity to bacterial infection8 Oct 2026US 2026/0306601 A1Syntiron LLC
- Development of carbohydrate-based anti-salmonella vaccines8 Oct 2026US 2026/0306602 A1Board of Trustees of Michigan State University
- Mucosal vaccines against tuberculosis8 Oct 2026US 2026/0306604 A1University of Houston System
- Combination Vaccine8 Oct 2026US 2026/0306615 A1Seqirus Inc.
Most cited
By later US patents
- Simultaneous stimulation and concentration of cells422US 6,797,514 B2XCYTE Therapies, Inc. · 2004
- Simultaneous stimulation and concentration of cells398US 6,867,041 B2XCYTE Therapies, Inc. · 2005
- Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant395US 6,406,705 B1Coley Pharmaceutical GmbH · 2002
- Simultaneous stimulation and concentration of cells383US 6,905,874 B2XCYTE Therapies, Inc. · 2005
- Vectors and methods for immunization or therapeutic protocols285US 6,339,068 B12002